feed,title,long_url,short_url
Benzinga,Relmada Aces REL-1017 Vs Ketamine Study For Abuse Potential,https://benzinga.com/general/biotech/22/02/25777686/relmada-aces-rel-1017-vs-ketamine-study-for-abuse-potential,https://bit.ly/3vdjYha
Benzinga,"Agilent's Q1 FY22 Earnings Beat Expectations, FY22 Guidance Surpass Street Estimates",https://benzinga.com/news/earnings/22/02/25781846/agilents-q1-fy22-earnings-beat-expectations-fy22-guidance-surpass-street-estimates,https://bit.ly/36tGQOV
Benzinga,Twitter To Raise $1B Via Private Placement Debt Offering,https://benzinga.com/news/22/02/25781175/twitter-to-raise-1b-via-private-placement-debt-offering,https://bit.ly/3JL5EAk
